HERTHENA-Lung01 is a phase II trial to evaluate the efficacy and safety of HER3-DXd in EGFR mutated NSCLC patients previously treated with EGFR TKI and platinum-based chemotherapy (27). The gene discussed is ERBB3; the disease is non-small cell lung carcinoma.